First Trust Advisors LP Buys 51,555 Shares of United Therapeutics Corporation $UTHR

First Trust Advisors LP lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 23.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 270,578 shares of the biotechnology company’s stock after buying an additional 51,555 shares during the period. First Trust Advisors LP’s holdings in United Therapeutics were worth $160,447,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Torren Management LLC bought a new position in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at about $31,000. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of a number of recent analyst reports. HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Bank of America reduced their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $644.82.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total value of $4,586,248.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,960,240.32. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $535.99, for a total transaction of $5,091,905.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $21,714,562.87. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 525,743 shares of company stock worth $293,954,527. Company insiders own 8.60% of the company’s stock.

United Therapeutics Stock Down 1.6%

United Therapeutics stock opened at $527.07 on Thursday. The firm has a 50 day moving average price of $549.61 and a 200-day moving average price of $531.18. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The company has a market capitalization of $22.37 billion, a P/E ratio of 19.46, a P/E/G ratio of 1.79 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the company posted $6.63 earnings per share. Equities analysts expect that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.